Depression and Fatigue in MS Patients Treated With Betaferon. (FADO)

Bayer

Status: Completed

Conditions: Multiple Sclerosis

Treatments: Biological: Interferon beta-1b (Betaferon, BAY86-5046)

Study type: Observational

Funder types: Industry

Identifiers

NCT01354665

BF1012PL (Other Identifier)

15307

Details and patient eligibility

About

This study aims to evaluate the occurence and severity of fatigue and depression in multiple sclerosis patients and the impact of Betaferon treatment on symptoms alterations.

The study is conducted in routine practice setting hence no interference with standard care takes place.

Pharmacologic treatments of MS-fatigue and depression will also be recorded.

Enrollment: 567 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Relapsing-remitting multiple sclerosis
• Age 18+
• Patients initiating Betaferon treatment

Exclusion criteria

• Patients previously treated with any immunomodulatory drug

Trial design

567 participants in 1 patient group

Group 1

Treatment:

Biological: Interferon beta-1b (Betaferon, BAY86-5046)